O'Meara Wendy Prudhomme, Smith David L, McKenzie F Ellis
Fogarty International Center, National Institutes of Health, Bethesda, Maryland, United States of America.
PLoS Med. 2006 May;3(5):e141. doi: 10.1371/journal.pmed.0030141. Epub 2006 Apr 4.
Treatment of asymptomatic individuals, regardless of their malaria infection status, with regularly spaced therapeutic doses of antimalarial drugs has been proposed as a method for reducing malaria morbidity and mortality. This strategy, called intermittent preventive treatment (IPT), is currently employed for pregnant women and is being studied for infants (IPTi) as well. As with any drug-based intervention strategy, it is important to understand how implementation may affect the spread of drug-resistant parasites. This is a difficult issue to address experimentally because of the limited size and duration of IPTi trials as well as the intractability of distinguishing the spread of resistance due to conventional treatment of malaria episodes versus that due to IPTi when the same drug is used in both contexts.
Using a mathematical model, we evaluated the possible impact of treating individuals with antimalarial drugs at regular intervals regardless of their infection status. We translated individual treatment strategies and drug pharmacokinetics into parasite population dynamic effects and show that immunity, treatment rate, drug decay kinetics, and presumptive treatment rate are important factors in the spread of drug-resistant parasites. Our model predicts that partially resistant parasites are more likely to spread in low-transmission areas, but fully resistant parasites are more likely to spread under conditions of high transmission, which is consistent with some epidemiological observations. We were also able to distinguish between spread of resistance due to treatment of symptomatic infections and that due to IPTi. We showed that IPTi could accelerate the spread of resistant parasites, but this effect was only likely to be significant in areas of low or unstable transmission.
The results presented here demonstrate the importance of considering both the half-life of a drug and the existing level of resistance when choosing a drug for IPTi. Drugs to which little or no resistance exists are not advisable for IPT in high-transmission areas, but IPTi is not likely to significantly impact the spread of highly resistant parasites in areas where partial resistance is already established. IPTi is more likely to accelerate the spread of resistance in high-transmission areas than is IPT in adults (i.e., pregnant women).
有人提出,无论无症状个体的疟疾感染状况如何,定期给予治疗剂量的抗疟药物可作为降低疟疾发病率和死亡率的一种方法。这种策略称为间歇性预防治疗(IPT),目前用于孕妇,也正在对婴儿进行研究(婴儿间歇性预防治疗[IPTi])。与任何基于药物的干预策略一样,了解实施过程如何影响耐药寄生虫的传播非常重要。由于IPTi试验的规模和持续时间有限,以及在两种情况下使用相同药物时,难以区分因常规治疗疟疾发作导致的耐药性传播与因IPTi导致的耐药性传播,因此这是一个难以通过实验解决的问题。
我们使用数学模型评估了无论感染状况如何定期用抗疟药物治疗个体可能产生的影响。我们将个体治疗策略和药物药代动力学转化为寄生虫种群动态效应,结果表明免疫力、治疗率、药物衰减动力学和推定治疗率是耐药寄生虫传播的重要因素。我们的模型预测,部分耐药的寄生虫在低传播地区更有可能传播,但完全耐药的寄生虫在高传播条件下更有可能传播,这与一些流行病学观察结果一致。我们还能够区分因治疗有症状感染导致的耐药性传播和因IPTi导致的耐药性传播。我们表明,IPTi可能会加速耐药寄生虫的传播,但这种效应仅在低传播或不稳定传播地区可能显著。
此处给出的结果表明,在为IPTi选择药物时,考虑药物半衰期和现有耐药水平非常重要。在高传播地区,几乎没有或不存在耐药性的药物不适合用于IPT,但在已经存在部分耐药性的地区,IPTi不太可能对高度耐药寄生虫的传播产生显著影响。与成人中的IPT(即孕妇)相比,IPTi在高传播地区更有可能加速耐药性的传播。